Status:
COMPLETED
MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Zhongda Hospital
Beijing 302 Hospital
Conditions:
Hypertension, Portal
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous pressure gradien...
Detailed Description
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous pressure gradien...
Eligibility Criteria
Inclusion
- Age 18-75 years
- With written informed consent
- Confirmed liver cirrhosis based on liver biopsy or clinical findings
- Scheduled to undergo clinically-indicated transjugular HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter
- Has undergone\> MR imaging within 14 days to hepatic vein catheterization
- No hepatic-portal vein interventional therapy between MR imaging and hepatic vein catheterization
Exclusion
- A contraindication to MR imaging, in particular pacemakers or implantable defibrillators, cochlear implants, neurosurgical clips, intra-orbital or brain metallic foreign bodies, endo prothesis since less than 4 weeks or osteosynthesis material since less than 6 weeks
- Unable to comply with breathing or other imaging related instructions resulting in inability to obtain diagnostic quality MR imaging studies
- Contraindication to the injection of contrast agent: pregnancy, lactation, history of allergic reaction to contrast agent injection.
- Prior transjugular intrahepatic portosystem stent-shunt surgery
- Prior devascularization operation
- Has received a liver transplant
- Any active, serious, life-threatening disease
Key Trial Info
Start Date :
December 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2019
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT03766880
Start Date
December 4 2018
End Date
April 30 2019
Last Update
August 28 2019
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 Hospital
Beijing, Beijing Municipality, China
2
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
3
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
4
Shunde Hospital, Southern Medical University
Shunde, Guangdong, China